Unsupervised quantum machine learning for fraud detection

We develop quantum protocols for anomaly detection and apply them to the task of credit card fraud detection (FD). First, we establish classical benchmarks based on supervised and unsupervised machine learning methods, where average precision is chosen as a robust metric for detecting anomalous data. We focus on kernel-based approaches for ease of direct comparison, basing our unsupervised modelling on one-class support vector machines (OC-SVM). Next, we employ quantum kernels of different type for performing anomaly detection, and observe that quantum FD can challenge equivalent classical protocols at increasing number of features (equal to the number of qubits for data embedding). Performing simulations with registers up to 20 qubits, we find that quantum kernels with re-uploading demonstrate better average precision, with the advantage increasing with system size. Specifically, at 20 qubits we reach the quantum-classical separation of average precision being equal to 15%. We discuss the prospects of fraud detection with near- and mid-term quantum hardware, and describe possible future improvements.Comment: 7 pages, 4 figure

Surface acoustic wave devices on bulk ZnO at low temperature

Surface acoustic wave (SAW) devices based on thin films of ZnO are a well established technology. However, SAW devices on bulk ZnO crystals are not practical at room temperature due to the significant damping caused by finite electrical conductivity of the crystal. Here, by operating at low temperatures, we demonstrate effective SAW devices on the (0001) surface of bulk ZnO crystals, including a delay line operating at SAW wavelengths of {\lambda} = 4 and 6 {\mu}m and a one-port resonator at a wavelength of {\lambda} = 1.6 {\mu}m. We find that the SAW velocity is temperature dependent, reaching $v \simeq 2.68$ km/s at 10mK. Our resonator reaches a maximum quality factor of $Q_i \simeq 1.5\times 10^5$, demonstrating that bulk ZnO is highly viable for low temperature SAW applications. The performance of the devices is strongly correlated with the bulk conductivity, which quenches SAW transmission above about 200 K.Comment: 4 pages, 3 figure

Microplastics in arctic invertebrates- Status on occurrence and recommendations for future monitoring

Few studies have been published on occurrence and distribution on microplastics (MPs) in invertebrates from the Arctic. We still need to develop harmonised methods to enable good comparison between studies taking into account recovery rates, size ranges, shapes and polymer types. Here, we review studies on MPs in invertebrates from the Arctic and present suggestions on sampling protocols and potential indicator species. Since information on MPs in Arctic invertebrates is vastly lacking, we recommend to at least include suspension feeding bivalves like mussels in monitoring programmes to function as indicator species in the Arctic. Mussels have also been suggested as indicator species for MP monitoring in coastal regions further south. Although we recognise the challenge with particle selection and egestion in mussels as well as the relatively low concentrations of MPs in Arctic waters, uptake levels seem to represent recent exposures. More research is needed to understand these selection processes and how they affect the bioaccumulation processes. Future research should include studies on whether different functional groups of invertebrates have different exposures to MPs, e.g., if there are differences between sessile versus motile species or different feeding strategies. More knowledge on monitoring strategies for pelagic and benthic species is needed.Microplastics in arctic invertebrates- Status on occurrence and recommendations for future monitoringpublishedVersio

Oculomotor Deficits after Chemotherapy in Childhood

Advances in the diagnosis and treatment of pediatric malignancies have substantially increased the number of childhood cancer survivors. However, reports suggest that some of the chemotherapy agents used for treatment can cross the blood brain barrier which may lead to a host of neurological symptoms including oculomotor dysfunction. Whether chemotherapy at young age causes oculomotor dysfunction later in life is unknown. Oculomotor performance was assessed with traditional and novel methods in 23 adults (mean age 25.3 years, treatment age 10.2 years) treated with chemotherapy for a solid malignant tumor not affecting the central nervous system. Their results were compared to those from 25 healthy, age-matched controls (mean age 25.1 years). Correlation analysis was performed between the subjective symptoms reported by the chemotherapy treated subjects (CTS) and oculomotor performance. In CTS, the temporal control of the smooth pursuit velocity (velocity accuracy) was markedly poorer (p<0.001) and the saccades had disproportionally shorter amplitude than normal for the associated saccade peak velocity (main sequence) (p = 0.004), whereas smooth pursuit and saccade onset times were shorter (p = 0.004) in CTS compared with controls. The CTS treated before 12 years of age manifested more severe oculomotor deficits. CTS frequently reported subjective symptoms of visual disturbances (70%), unsteadiness, light-headedness and that things around them were spinning or moving (87%). Several subjective symptoms were significantly related to deficits in oculomotor performance. To conclude, chemotherapy in childhood or adolescence can result in severe oculomotor dysfunctions in adulthood. The revealed oculomotor dysfunctions were significantly related to the subjects’ self-perception of visual disturbances, dizziness, light-headedness and sensing unsteadiness. Assessments of oculomotor function may, thus, offer an objective method to track and rate the level of neurological complications following chemotherapy

Decreased postural control in adult survivors of childhood cancer treated with chemotherapy

© 2016 The Authors. Published by Nature Research. This is an open access article available under a Creative Commons licence. The published version can be accessed at the following link on the publisher’s website: https://doi.org/10.1038/srep36784The objective of cancer treatment is to secure survival. However, as chemotherapeutic agents can affect the central and peripheral nervous systems, patients must undergo a process of central compensation. We explored the effectiveness of this compensation process by measuring postural behaviour in adult survivors of childhood cancer treated with chemotherapy (CTS). We recruited sixteen adults treated with chemotherapy in childhood for malignant solid (non-CNS) tumours and 25 healthy age-matched controls. Subjects performed posturography with eyes open and closed during quiet and perturbed standing. Repeated balance perturbations through calf vibrations were used to study postural adaptation. Subjects were stratified into two groups (treatment before or from 12 years of age) to determine age at treatment effects. Both quiet (p = 0.040) and perturbed standing (p ≤ 0.009) were significantly poorer in CTS compared to controls, particularly with eyes open and among those treated younger. Moreover, CTS had reduced levels of adaptation compared to controls, both with eyes closed and open. Hence, adults treated with chemotherapy for childhood cancer may suffer late effects of poorer postural control manifested as reduced contribution of vision and as reduced adaptation skills. These findings advocate development of chemotherapeutic agents that cause fewer long-term side effects when used for treating children.The authors’ wish to acknowledge the financial supported from the Swedish Medical Research Council (grant nr. 17x-05693), the Medical Faculty, Lund University, Sweden and the Skåne County Council’s research and development foundation.Published versio

The power of multi-matrix monitoring in the Pan-Arctic region: plastics in water and sediment

Litter and microplastic assessments are being carried out worldwide. Arctic ecosystems are no exception and plastic pollution is high on the Arctic Council's agenda. Water and sediment have been identified as two of the priority compartments for monitoring plastics under the Arctic Monitoring and Assessment Programme (AMAP). Recommendations for monitoring both compartments are presented in this publication. Alone, such samples can provide information on presence, fate, and potential impacts to ecosystems. Together, the quantification of microplastics in sediment and water from the same region produce a three-dimensional picture of plastics, not only a snapshot of floating or buoyant plastics in the surface water or water column but also a picture of the plastics reaching the shoreline or benthic sediments, in lakes, rivers, and the ocean. Assessment methodologies must be adapted to the ecosystems of interest to generate reliable data. In its current form, published data on plastic pollution in the Arctic is sporadic and collected using a wide spectrum of methods which limits the extent to which data can be compared. A harmonised and coordinated effort is needed to gather data on plastic pollution for the Pan-Arctic. Such information will aid in identifying priority regions and focusing mitigation efforts.publishedVersio

Policies for biosimilar uptake in Europe : an overview

Background: Across European countries, differences exist in biosimilar policies, leading to variations in uptake of biosimilars and divergences in savings all over Europe. Objectives: The aim of this article is to provide an overview of different initiatives and policies that may influence the uptake of biosimilars in different European countries. Recommendations will be formulated on how to create sustainable uptake. Methods: An overview of policies on biosimilars was obtained via a questionnaire, supplemented with relevant articles. Topics were organized in five themes: availability, pricing, reimbursement, demand-side policies, and recommendations to enhance uptake. Results: In all countries studied, biological medicines are available. Restrictions are mainly dependent on local organization of the healthcare system. Countries are willing to include biosimilars for reimbursement, but for commercial reasons they are not always marketed. In two thirds of countries, originator and biosimilar products may be subjected to internal reference pricing systems. Few countries have implemented specific incentives targeting physicians. Several countries are implementing pharmacist substitution; however, the scope and rules governing such substitution tend to vary between these countries. Reported educational policies tend to target primarily physicians, whereas fewer initiatives were reported for patients. Recommendations as proposed by the different country experts ranged from the need for information and communication on biosimilars to competitive pricing, more support for switching and guidance on substitution. Conclusions: Most countries have put in place specific supply-side policies for promoting access to biosimilars. To supplement these measures, we propose that investments should be made to clearly communicate on biosimilars and educate stakeholders. Especially physicians need to be informed on the entry and use of biosimilars in order to create trust. When physicians are well-informed on the treatment options, further incentives should be offered to prescribe biosimilars. Gainsharing can be used as an incentive to prescribe, dispense or use biosimilars. This approach, in combination with binding quota, may support a sustainable biosimilar market

Payers' views of the changes arising through the possible adoption of adaptive pathways

Payers are a major stakeholder in any considerations and initiatives concerning adaptive licensing of new medicinal products, also referred to as Medicines Adaptive Pathways to patients (MAPPs). Firstly, the scope and necessity of MAPPs need further scrutiny, especially with regard to the definition of unmet need. Conditional approval pathways already exist for new medicines for seriously debilitating or life-threatening diseases and only a limited number of new medicines are innovative. Secondly, MAPPs will result in new medicines on the market with limited evidence about their effectiveness and safety. Additional data are to be collected after approval. Consequently, adaptive pathways may increase the risk of exposing patients to ineffective or unsafe medicines. We have already seen medicines approved conventionally that subsequently proved ineffective or unsafe amongst a wider, more co-morbid population as well as medicines that could have been considered for approval under MAPPs but subsequently proved ineffective or unsafe in Phase III trials and were never licensed. Thirdly, MAPPs also put high demands on payers. Routine collection of patient level data is difficult with high transaction costs. It is not clear who will fund these. Other challenges for payers include shifts in the risk governance framework, implications for evaluation and HTA, increased complexity of setting prices, difficulty with ensuring equity in the allocation of resources, definition of responsibility and liability and implementation of stratified use. Exit strategies also need to be agreed in advance, including price reductions, rebates, or reimbursement withdrawals when price premiums are not justified. These issues and concerns will be discussed in detail including potential ways forward

Generic pregabalin : current situation and implications for health authorities, generics and biosimilars manufacturers in the future

The manufacturer of pregabalin has a second use patent covering prescribing for neuropathic pain: its principal indication. The manufacturer has threatened legal action in the UK if generic pregabalin rather than Lyrica is prescribed for this indication. No problems exist for practitioners who prescribe pregabalin for epilepsy or generalized anxiety disorder. This has serious implications for health authorities. In Germany, however, generics could be legally prescribed for any approved indication once one indication loses its patent. We aim to establish the current situation with pregabalin among principally European countries. Personnel from 33 regional and national health authorities mainly from Europe, and nine from universities across Europe working as advisers to health authorities or with insight into their activities, were surveyed regarding four specific questions via email to shed light on the current situation with Lyrica and pregabalin in their country. The information collated from each country was subsequently checked for accuracy with each co-author by email and face-to-face contact and collated into five tables. The scenarios ranged from extending the patent life of Lyrica (e.g. France), endorsing the prescribing of Lyrica for neuropathic pain (e.g. Catalonia and South Korea), and current prescribing of pregabablin for all indications (e.g. Serbia and Germany). Little activity has taken place in European countries in which generic pregabalin is not yet reimbursed. The availability of generic pregabalin has prompted a number of different activities to be undertaken among the 33 countries and regions surveyed. The situation in Serbia and the historic situation in Germany provide examples of ways to maximize savings once a product loses its patent for at least one indication